9 results
Evaluation of the effect of daratumumab in combination with ATRA in patients with relapsed/refractory multiple myeloma
The primary objective of this study is to compare the overall survival (OS) of ramucirumab DP administered in combination with docetaxel versus docetaxel with placebo as therapy for patients with Stage IV non-small cell lung cancer (NSCLC) who have…
PrimaryTo assess the effect of GLPG1205 on the single dose pharmacokinetics (PK) of an OCT2 probe substrate, metformin, in healthy male subjects.To assess the effect of GLPG1205 on the single dose pharmacokinetics (PK) of a BCRP probe substrate,…
Primary objective: To test for the first time in a double-blind randomized, placebo controlled trial whether three years treatment with metformin 1000 mg bd added to titrated insulin therapy (towards target HbA1c 7.0%/ 53 mmol/mol) reduces…
The study aims to limit the use of anthracyclines and to reduce the dose of ATRA. Another aim is to stratify treatment by risk group: standard risk - WBC <10 x 109/l : high risk - WBC >=10 x 109/l. Furthermore this study aims to…
The primary objective of this study is to compare overall survival (OS) in patients with metastatic colorectal carcinoma (CRC) when treated with FOLFIRI in combination with placebo versus FOLFIRI in combination with ramucirumab DP.Secondary…
The primary objective is to compare the overall survival (OS; time from randomization to death) in patients with hepatocellular carcinoma (HCC) who had disease progression during or following sorafenib therapy, or were intolerant to this agent.…
Treatment of overweight persons with insulinresistance with a low dose metformin added to yoghurt. The early reduction of glucose, especially the postprandial glucose will hopefully slow the process from insuline resistance to diabetes mellitus.…
Primary objectives:* Part 1: To evaluate the safety and tolerability and determine the recommended dose(s) of INCB059872 for further study in advancedmalignancies.* Part 2: To further evaluate the safety and tolerability of INCB059872 for further…